131 related articles for article (PubMed ID: 38937146)
1. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
Ross L; Hansen D; Proudman S; Khanna D; Herrick AL; Stevens W; ; ; Baron M; Nikpour M;
Arthritis Rheumatol; 2024 Jun; ():. PubMed ID: 38937146
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
[TBL] [Abstract][Full Text] [Related]
3. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
[TBL] [Abstract][Full Text] [Related]
4. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
5. Performance of the 2017 EUSTAR activity index in an scleroderma cohort.
Ross L; Stevens W; Wilson M; Huq M; Strickland G; Walker J; Sahhar J; Ngian GS; Roddy J; Youssef P; Proudman S; Nikpour M
Clin Rheumatol; 2020 Dec; 39(12):3701-3705. PubMed ID: 32696281
[TBL] [Abstract][Full Text] [Related]
6. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
[TBL] [Abstract][Full Text] [Related]
7. Outcome measurements in scleroderma: results from a delphi exercise.
Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
[TBL] [Abstract][Full Text] [Related]
8. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.
Baron M; Kahaleh B; Bernstein EJ; Chung L; Clements PJ; Denton C; Domsic RT; Ferdowsi N; Foeldvari I; Frech T; Gordon JK; Hudson M; Johnson SR; Khanna D; McMahan Z; Merkel PA; Narain S; Nikpour M; Pauling JD; Ross L; Valenzuela Vergara AM; Vacca A
J Scleroderma Relat Disord; 2019 Feb; 4(1):17-27. PubMed ID: 30906878
[TBL] [Abstract][Full Text] [Related]
9. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
Baron M; Hudson M; Steele R; Lo E;
J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
[TBL] [Abstract][Full Text] [Related]
10. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
[TBL] [Abstract][Full Text] [Related]
11. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
[TBL] [Abstract][Full Text] [Related]
12. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
[TBL] [Abstract][Full Text] [Related]
13. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0.
Ozeri D; Peretz S; Oppenheim A; Watad A; Lidar M; Braun-Moscovici Y
J Scleroderma Relat Disord; 2023 Feb; 8(1):31-35. PubMed ID: 36743811
[TBL] [Abstract][Full Text] [Related]
15. Quality indicator set for systemic sclerosis.
Khanna D; Kowal-Bielecka O; Khanna PP; Lapinska A; Asch SM; Wenger N; Brown KK; Clements PJ; Getzug T; Mayes MD; Medsger TA; Oudiz R; Simms R; Steen V; Maranian P; Furst DE
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S33-9. PubMed ID: 21586216
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
[TBL] [Abstract][Full Text] [Related]
17. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
[TBL] [Abstract][Full Text] [Related]
18. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17-item Scleroderma Functional scale.
Daste C; Abdoul H; Foissac F; Papelard A; Alami S; Kwakkenbos L; Carrier ME; Lefèvre-Colau MM; Thombs BD; Poiraudeau S; Rannou F; Mouthon L; Nguyen C
Br J Dermatol; 2020 Oct; 183(4):710-718. PubMed ID: 32017013
[TBL] [Abstract][Full Text] [Related]
19. Long-term organ damage accrual and late mortality in systemic sclerosis.
Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
[TBL] [Abstract][Full Text] [Related]
20. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
